Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma

BackgroundTumor models are critical for our understanding of cancer and the development of cancer therapeutics. Here, we present an integrated map of the genome, transcriptome and immunome of an epithelial mouse tumor, the CT26 colon carcinoma cell line.ResultsWe found that Kras is homozygously mutated at p.G12D, Apc and Tp53 are not mutated, and Cdkn2a is homozygously deleted. Proliferation and stem-cell markers, including Top2a, Birc5 (Survivin), Cldn6 and Mki67, are highly expressed while differentiation and top-crypt markers Muc2, Ms4a8a (MS4A8B) and Epcam are not. Myc, Trp53 (tp53), Mdm2, Hif1a, and Nras are highly expressed while Egfr and Flt1 are not. MHC class I but not MHC class II is expressed. Several known cancer-testis antigens are expressed, including Atad2, Cep55, and Pbk. The highest expressed gene is a mutated form of the mouse tumor antigen gp70. Of the 1,688 non-synonymous point variations, 154 are both in expressed genes and in peptides predicted to bind MHC and thus potential targets for immunotherapy development. Based on its molecular signature, we predicted that CT26 is refractory to anti-EGFR mAbs and sensitive to MEK and MET inhibitors, as have been previously reported.ConclusionsCT26 cells share molecular features with aggressive, undifferentiated, refractory human colorectal carcinoma cells. As CT26 is one of the most extensively used syngeneic mouse tumor models, our data provide a map for the rationale design of mode-of-action studies for pre-clinical evaluation of targeted- and immunotherapies.

[1]  J. Mesirov,et al.  GenePattern 2.0 , 2006, Nature Genetics.

[2]  Ken Chen,et al.  SomaticSniper: identification of somatic point mutations in whole genome sequencing data , 2012, Bioinform..

[3]  Zhiyong Lu,et al.  Database resources of the National Center for Biotechnology Information , 2010, Nucleic Acids Res..

[4]  A. Eggermont,et al.  Gene expression profiling of primary cutaneous melanoma and clinical outcome. , 2006, Journal of the National Cancer Institute.

[5]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[6]  A. Sparks,et al.  The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.

[7]  M. Serrano,et al.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.

[8]  P. V. van Diest,et al.  Oncogenic KRAS desensitizes colorectal tumor cells to epidermal growth factor receptor inhibition and activation. , 2010, Neoplasia.

[9]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[10]  J. Castle,et al.  HLA typing from RNA-Seq sequence reads , 2012, Genome Medicine.

[11]  Piotr J. Balwierz,et al.  Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. , 2013, Cancer cell.

[12]  Lewis C Cantley,et al.  A colorectal cancer classification system that associates cellular phenotype and responses to therapy , 2013, Nature Medicine.

[13]  Cole Trapnell,et al.  Ultrafast and memory-efficient alignment of short DNA sequences to the human genome , 2009, Genome Biology.

[14]  Oliver Hofmann,et al.  Genome-wide analysis of cancer/testis gene expression , 2008, Proceedings of the National Academy of Sciences.

[15]  I. Mellman,et al.  Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity , 2012, Proceedings of the National Academy of Sciences.

[16]  Gregory D. Schuler,et al.  Database resources of the National Center for Biotechnology Information: update , 2004, Nucleic acids research.

[17]  G. Packham,et al.  FOXO3 expression during colorectal cancer progression: biomarker potential reflects a tumour suppressor role , 2013, British Journal of Cancer.

[18]  J. Castle,et al.  Exploiting the mutanome for tumor vaccination. , 2012, Cancer research.

[19]  M. J. van de Vijver,et al.  Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. , 2011, Cell stem cell.

[20]  S. Goerdt,et al.  Identification of the novel differentiation marker MS4A8B and its murine homolog MS4A8A in colonic epithelial cells lost during neoplastic transformation in human colon , 2013, Cell Death and Disease.

[21]  Raymond K. Auerbach,et al.  A User's Guide to the Encyclopedia of DNA Elements (ENCODE) , 2011, PLoS biology.

[22]  Jill P. Mesirov,et al.  GSEA-P: a desktop application for Gene Set Enrichment Analysis , 2007, Bioinform..

[23]  Mira Ayadi,et al.  Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value , 2013, PLoS medicine.

[24]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[25]  Kimberly R. Jordan,et al.  Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens , 2010, Proceedings of the National Academy of Sciences.

[26]  Pornpimol Charoentong,et al.  ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks , 2009, Bioinform..

[27]  Florian Markowetz,et al.  Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions , 2013, Nature Medicine.

[28]  T. Eguchi,et al.  RB silencing compromises the DNA damage-induced G2/M checkpoint and causes deregulated expression of the ECT2 oncogene , 2007, Oncogene.

[29]  C. Der,et al.  KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer , 2009, Molecular Cancer Therapeutics.

[30]  T. Corbett,et al.  A colon tumor model for anticancer agent evaluation , 1975, Cancer.

[31]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[32]  Bjoern Peters,et al.  Applications for T-cell epitope queries and tools in the Immune Epitope Database and Analysis Resource. , 2011, Journal of immunological methods.

[33]  H. Clevers,et al.  Identification of stem cells in small intestine and colon by marker gene Lgr5 , 2007, Nature.

[34]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[35]  E. Furth,et al.  Serum antibodies to EpCAM in healthy donors but not ulcerative colitis patients , 2006, Cancer Immunology, Immunotherapy.

[36]  Ronghua Chen,et al.  DNA copy number, including telomeres and mitochondria, assayed using next-generation sequencing , 2010, BMC Genomics.

[37]  Lincoln Stein,et al.  Reactome: a knowledgebase of biological pathways , 2004, Nucleic Acids Res..

[38]  N. Matsubara,et al.  BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum , 2004, Gut.

[39]  Jennifer A. McWilliams,et al.  Age-dependent tolerance to an endogenous tumor-associated antigen. , 2008, Vaccine.

[40]  Andrew J. G. Simpson,et al.  CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens , 2008, Nucleic Acids Res..

[41]  L. Old,et al.  Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma , 1977, The Journal of experimental medicine.

[42]  Ming Li,et al.  An Immunosurveillance Mechanism Controls Cancer Cell Ploidy , 2012, Science.

[43]  K. Kinzler,et al.  Epitope landscape in breast and colorectal cancer. , 2008, Cancer research.

[44]  Pradeep S Rajendran,et al.  Single-cell dissection of transcriptional heterogeneity in human colon tumors , 2011, Nature Biotechnology.

[45]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[46]  J. Christensen,et al.  A Selective Small Molecule c-MET Inhibitor, PHA665752, Cooperates with Rapamycin , 2005, Clinical Cancer Research.

[47]  X. Bian,et al.  EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin , 2012, Oncogene.

[48]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[49]  K. Rex,et al.  c-Met Inhibitors with Novel Binding Mode Show Activity against Several Hereditary Papillary Renal Cell Carcinoma-related Mutations* , 2008, Journal of Biological Chemistry.

[50]  H. Clevers,et al.  Wnt signaling in the intestinal epithelium: from endoderm to cancer. , 2005, Genes & development.

[51]  Bixiang Zhang,et al.  Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer. , 2009, Cancer letters.